Načítá se...

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor

BACKGROUND AND OBJECTIVE: Verinurad (RDEA3170) is a high-affinity, selective URAT1 transporter inhibitor in development for treating gout and asymptomatic hyperuricemia. This Phase I, single-dose study investigated the pharmacokinetics, pharmacodynamics, and safety of verinurad in adults with renal...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Drug Investig
Hlavní autoři: Smith, William B., Hall, Jesse, Berg, Jolene K., Kazimir, Michal, Yamamoto, Amy, Walker, Susan, Lee, Caroline A., Shen, Zancong, Wilson, David M., Zhou, Dongmei, Gillen, Michael, Marbury, Thomas C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2018
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6061379/
https://ncbi.nlm.nih.gov/pubmed/29949102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-018-0652-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!